We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Animalcare Group Plc | LSE:ANCR | London | Ordinary Share | GB0032350695 | ORD 20P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.00 | 0.43% | 231.00 | 224.00 | 238.00 | 238.00 | 230.00 | 230.00 | 16,034 | 09:25:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Veterinary Service-livestock | 71.62M | 1.97M | 0.0327 | 70.64 | 138.83M |
TIDMANCR
RNS Number : 3898M
Animalcare Group PLC
21 January 2021
ANIMALCARE GROUP PLC
(the "Company" or the "Group")
Trading update and Notice of 2020 Full Year Results
21 January 2021. Animalcare Group plc (AIM: ANCR), the international animal health business, provides the following unaudited trading update for the 12 months ended 31 December 2020. Full year results are due to be published on 30 March 2021.
Highlights
-- Group trading performance demonstrates resilience in face of COVID-19 pandemic -- Revenues and earnings ahead of market expectations -- Cash conversion rate significantly improved in second half -- Net debt further reduced, down 23% year-on-year to approximately GBP13.6 million at year end
Trading overview
Revenues and earnings for the full year were ahead of market expectations. Despite significant disruption to the animal health market caused by COVID-19, 2020 revenues were GBP70.5 million (2019: GBP71.1 million), a decline of 0.7% year-on-year (2.0% decline at CER). Reflecting government counter measures and the adjustments made by the Group and veterinary customers over the course of the pandemic, revenues for the six months to the end of December were ahead of the prior year with sales up 3.0% to GBP36.0 million (2019: GBP35.0 million).
As projected, cash conversion improved in the second half of the year as the Group's stock profile returned nearer to historic levels. We expect average cash conversion for 2019 and 2020 combined to be above 100% of Underlying EBITDA, demonstrating our ability to generate strong and sustained levels of cash.
We further reduced net debt to approximately GBP13.6 million at the end of 2020, largely as a result of the second half improvement in cash conversion. This equates to a year-on-year reduction in net debt of 23% compared to GBP17.8 million as at 31 December 2019. The Group's improving financial position provides capacity for further investment in business development and pipeline opportunities that support our long-term growth strategy.
Commercial developments
Kevin Cole has been appointed President and CEO of STEM Animal Health Inc., the subsidiary created from the recently formed joint venture with Canada-based Kane Biotech Inc. Kevin will focus on building STEM Animal Health Inc. into a globally recognised brand in biofilm-targeting technology with an emphasis on developing sales channels and penetrating the growing companion animal sector. The Group expects to launch biofilm products across its markets in the second half of 2021.
Animalcare's novel COX-2 inhibitor (E-6087) for treatment of pain in dogs continues to make progress through the regulatory process. Plans for a launch across markets in the second half of 2021, subject to approval, are well advanced.
Jenny Winter, Chief Executive Officer commented: "Animalcare's resilience and agility came to the fore in 2020. Our trading performance during the continuing COVID-19 threat has further strengthened the Group, enabling us to continue investment in our long-term growth strategy. We asked our colleagues to rise to these challenges and I am proud of what they have delivered."
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
About Animalcare
Animalcare Group PLC is a UK AIM-listed international veterinary sales and marketing organisation. Animalcare operates in seven countries and exports to approximately 32 countries in Europe and a further 16 worldwide. The Group is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition.
For more information about Animalcare, please visit www.animalcaregroup.com or contact:
Animalcare Jenny Winter, Chief Executive Officer +44 (0)1904 487 687 Chris Brewster, Chief Financial Officer communications@animalcaregroup.com Media relations Panmure Gordon (Nominated Adviser & Broker) Corporate Finance Freddy Crossley/Emma Earl Corporate Broking Rupert Dearden +44 (0)20 7886 2500
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TSTDDGDBCSDDGBG
(END) Dow Jones Newswires
January 21, 2021 02:00 ET (07:00 GMT)
1 Year Animalcare Chart |
1 Month Animalcare Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions